Myriad myRisk® Hereditary Cancer Test
Enhanced with riskScore®

Know their risk.
Protect their future.

Myriad myRisk with riskScore blends analysis of genetic risk factors with clinical and cancer family history to deliver the most comprehensive, clinically actionable results to help providers manage their patients’ risk of cancer.

Why cancer risk assessment and testing

There is extensive support among leading medical organizations for the utilization of cancer risk assessment and testing due to the high prevalence of at-risk patients and proven success of medical interventions to improve patient outcomes.

Why Myriad myRisk

Myriad is your trusted advisor
with the Myriad myRisk Hereditary Cancer Test

Analytical Validity

Analytically validated high-throughput laboratory with 99.98% accuracy10

Variant Interpretation

Industry leading, FDA-reviewed11 variant interpretation program, as part of the BRACAnalysis CDx PMA, with powerful methods unique to Myriad

Lifetime commitment to patients & providers

In a study of over 1.6 million patients who underwent testing between 2006 & 2016, Myriad provided more than 60,000 results with definitive classifications for previously unknown VUSs, providing clarity for patients and providers12

“I knew I wanted to find out whether I’d inherited the genetic mutation so I could do what I could to combat it.”

Victoria R.
Hereditary Cancer Screen patient,
negative for BRCA1 and BRCA2

References

  1. DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the CommunityPractice Setting. Obstetrics & Gynecology 2018 - published online before print October 10, 2018.
  2. Bellcross CA, et al. Genet Med. 2015;17(1):43–50.
  3. Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340, 77–84 (1999).
  4. Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616–1622 (2002).
  5. Plevritis, S et al. Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA. 295(20), 2374–2384 (2006).
  6. de Jong, A. E. et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130, 665–671 (2006).
  7. ACOG Committee Opinion: Hereditary Cancer Syndromes and Risk Assessment, No. 634. June 2015, Reaffirmed 2017.
  8. Risk assessment, genetic counseling, and genetic testing for BRCArelated cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Feb 18;160(4):271-81.
  9. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V2.2019. Available at http://www.nccn.org.
  10. Judkins T. et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk; BMC Cancer, 2014.
  11. U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH). BRACAnalysis CDxTM approval letter, December 19, 2014. Retrieved November 7, 2018, from http://www.accessdata.fda.gov/cdrh_docs/pdf14/P140020A.pdf.
  12. Mersch J, et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. JAMA - published online September 25, 2018.